173 related articles for article (PubMed ID: 37058101)
1. Improved Rod Sensitivity as Assessed by Two-Color Dark-Adapted Perimetry in Patients With RPE65-Related Retinopathy Treated With Voretigene Neparvovec-rzyl.
Ku CA; Igelman AD; Huang SJ; Vasconcelos H; da Palma MM; Bailey ST; Lauer AK; Weleber RG; Yang P; Pennesi ME
Transl Vis Sci Technol; 2023 Apr; 12(4):17. PubMed ID: 37058101
[TBL] [Abstract][Full Text] [Related]
2. Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector.
Ku CA; Igelman AD; Huang SJ; Bailey ST; Lauer AK; Duncan JL; Weleber RG; Yang P; Pennesi ME
Transl Vis Sci Technol; 2024 Jun; 13(6):11. PubMed ID: 38888288
[TBL] [Abstract][Full Text] [Related]
3. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
[TBL] [Abstract][Full Text] [Related]
4. Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec.
Stingl K; Kempf M; Bartz-Schmidt KU; Dimopoulos S; Reichel F; Jung R; Kelbsch C; Kohl S; Kortüm FC; Nasser F; Peters T; Wilhelm B; Wissinger B; Wozar F; Zrenner E; Fischer MD; Stingl K
Br J Ophthalmol; 2022 Jun; 106(6):831-838. PubMed ID: 33472769
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
6. Two-Color Dark-Adapted Perimetry Implemented With a Commercially Available Perimeter to Characterize Rod-Pathway Sensitivity.
Igelman AD; Park JC; Hyde RA; Everett L; Yang P; Pennesi ME; McAnany JJ
Ophthalmic Surg Lasers Imaging Retina; 2022 Dec; 53(12):692-696. PubMed ID: 36547964
[TBL] [Abstract][Full Text] [Related]
7. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.
Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA
JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398
[TBL] [Abstract][Full Text] [Related]
9. The first gene therapy for
Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
[TBL] [Abstract][Full Text] [Related]
10. Full-field Scotopic Threshold Improvement after Voretigene Neparvovec-rzyl Treatment Correlates with Chorioretinal Atrophy.
Stingl K; Stingl K; Schwartz H; Reid MW; Kempf M; Dimopoulos S; Kortuem F; Borchert MS; Lee TC; Nagiel A
Ophthalmology; 2023 Jul; 130(7):764-770. PubMed ID: 36822437
[TBL] [Abstract][Full Text] [Related]
11. The RUSH2A Study: Dark-Adapted Visual Fields in Patients With Retinal Degeneration Associated With Biallelic Variants in the USH2A Gene.
Birch DG; Samarakoon L; Melia M; Duncan JL; Ayala AR; Audo I; Cheetham JK; Durham TA; Iannaccone A; Pennesi ME; Stingl K;
Invest Ophthalmol Vis Sci; 2022 Mar; 63(3):17. PubMed ID: 35293952
[TBL] [Abstract][Full Text] [Related]
12. Voretigene Neparvovec Gene Therapy in Clinical Practice: Treatment of the First Two Italian Pediatric Patients.
Testa F; Melillo P; Della Corte M; Di Iorio V; Brunetti-Pierri R; Citro A; Ferrara M; Karali M; Annibale R; Banfi S; Rossi S; Simonelli F
Transl Vis Sci Technol; 2021 Aug; 10(10):11. PubMed ID: 34554209
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic
Kiraly P; Cottriall CL; Taylor LJ; Jolly JK; Cehajic-Kapetanovic J; Yusuf IH; Martinez-Fernandez de la Camara C; Shanks M; Downes SM; MacLaren RE; Fischer MD
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892166
[TBL] [Abstract][Full Text] [Related]
14. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
15. Effect of Pharmacological Pupil Dilation on Dark-Adapted Perimetric Sensitivity in Healthy Subjects Using an Octopus 900 Perimeter.
Igelman AD; Ku C; Mershon S; da Palma MM; McAnany JJ; Hyde RA; Park JC; Yang P; Pennesi ME
Transl Vis Sci Technol; 2021 Dec; 10(14):18. PubMed ID: 34919129
[TBL] [Abstract][Full Text] [Related]
16. Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures.
Roman AJ; Schwartz SB; Aleman TS; Cideciyan AV; Chico JD; Windsor EA; Gardner LM; Ying GS; Smilko EE; Maguire MG; Jacobson SG
Exp Eye Res; 2005 Feb; 80(2):259-72. PubMed ID: 15670804
[TBL] [Abstract][Full Text] [Related]
17. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.
Lopez J; Borchert M; Lee TC; Nagiel A
Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501
[TBL] [Abstract][Full Text] [Related]
18. Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.
Sengillo JD; Gregori NZ; Sisk RA; Weng CY; Berrocal AM; Davis JL; Mendoza-Santiesteban CE; Zheng DD; Feuer WJ; Lam BL
Ophthalmol Retina; 2022 Apr; 6(4):273-283. PubMed ID: 34896323
[TBL] [Abstract][Full Text] [Related]
19. Blue cone monochromacy: visual function and efficacy outcome measures for clinical trials.
Luo X; Cideciyan AV; Iannaccone A; Roman AJ; Ditta LC; Jennings BJ; Yatsenko SA; Sheplock R; Sumaroka A; Swider M; Schwartz SB; Wissinger B; Kohl S; Jacobson SG
PLoS One; 2015; 10(4):e0125700. PubMed ID: 25909963
[TBL] [Abstract][Full Text] [Related]
20. The application of chromatic dark-adapted kinetic perimetry to retinal diseases.
Rotenstreich Y; Fishman GA; Lindeman M; Alexander KR
Ophthalmology; 2004 Jun; 111(6):1222-7. PubMed ID: 15177975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
